evidence/gaps
Cochrane · systematic review · CD010615

Additional plerixafor to granulocyte colony‐stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma

Hartmann, T, Hübel, K, Monsef, I, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library

HaematologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
3
No studies
4
Included studies
NR
No studies 4 · 57.1%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 14.3%High 2 · 28.6%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Plerixafor versus placebo for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma

Population: People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma
7 questions
OutcomeEffectEvidenceStatus / GRADE
Mortality (12 months)
Plerixafor vs placebo
RR 1 [0.59, 1.69]2 studies · 600 participantsModerate
Downgraded: imprecision
Quality of life
Plerixafor vs placebo
no estimate extractedNRNo studies
Progression‐free survival
Plerixafor vs placebo
no estimate extractedNRNo studies
Time to engraftment
Plerixafor vs placebo
no estimate extractedNRNo studies
Number of transplanted participants
Plerixafor vs placebo
no estimate extractedNRNo studies
Successful stem cell collection
Plerixafor vs placebo
RR 2.42 [1.98, 2.96]2 studies · 600 participantsHigh
Adverse events (during stem cell mobilisation and collection)
Plerixafor vs placebo
RR 1.02 [0.99, 1.06]2 studies · 593 participantsHigh